Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies.
Minarik J et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jan 5. doi: 10.5507/bp.2015.064. [Epub ahead of print].

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW et al. Clin Chem Lab Med. 2016 Jan 21. pii: /j/cclm.ahead-of-print/cclm-2015-0888/cclm-2015-0888.xml. doi: 10.1515/cclm-2015-0888. [Epub ahead of print].

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma.

Krishnan SR et al. Neoplasia. 2016 Jan;18(1):25-32. doi: 10.1016/j.neo.2015.11.011.

Implemented myeloma management with whole-body low-dose CT scan: a real life experience.

Mangiacavalli S et al. Leuk Lymphoma. 2016 Jan 20:1-7. [Epub ahead of print].

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.

Ting KR et al. Br J Haematol. 2016 Jan 20. doi: 10.1111/bjh.13928. [Epub ahead of print].

Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.

[No authors listed] Cytometry B Clin Cytom. 2016 Jan;90(1):9-10. doi: 10.1002/cyto.b.21342.

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW et al. J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016. [Epub ahead of print].

Bone marrow invasion in multiple myeloma and metastatic disease.

Vilanova JC et al. Radiologia. 2016 Jan 4. pii: S0033-8338(15)00200-3. doi: 10.1016/j.rx.2015.11.002. [Epub ahead of print].

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.

Mai EK et al. Eur Radiol. 2016 Jan 15. [Epub ahead of print].

Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.

Fukumoto K et al. Leuk Lymphoma. 2016 Jan 13:1-7. [Epub ahead of print].

Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.

Tacchetti P et al. Leuk Lymphoma. 2016 Jan 14:1-7. [Epub ahead of print].

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Paiva B et al. Blood. 2016 Jan 11. pii: blood-2015-08-665679. [Epub ahead of print].

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. 
Muz B et al. Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13927. [Epub ahead of print].

Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma.

Rades D et al. Anticancer Res. 2016 Jan;36(1):375-8.

Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned.

Bier G et al. AJR Am J Roentgenol. 2016 Jan;206(1):57-63. doi: 10.2214/AJR.15.15089